...
首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >An AS1411 aptamer-conjugated liposomal system containing a bubble-generating agent for tumor-specific chemotherapy that overcomes multidrug resistance
【24h】

An AS1411 aptamer-conjugated liposomal system containing a bubble-generating agent for tumor-specific chemotherapy that overcomes multidrug resistance

机译:一种AS1411适体缀合的脂质体系统,该系统包含用于肿瘤特异性化学疗法的气泡产生剂,可克服多药耐药性

获取原文
获取原文并翻译 | 示例
           

摘要

Recent research in chemotherapy has prioritized overcoming the multidrug resistance (MDR) of cancer cells. In this work, liposomes that contain doxorubicin (DOX) and ammonium bicarbonate (ABC, a bubble-generating agent) are prepared and functionalized with an antinucleolin aptamer (AS1411 liposomes) to target DOX-resistant breast cancer cells (MCF-7/ADR), which overexpress nucleolin receptors. Free DOX and liposomes without functionalization with AS1411 (plain liposomes) were used as controls. The results of molecular dynamic simulations suggest that AS1411 functionalization may promote the affinity and specific binding of liposomes to the nucleolin receptors, enhancing their subsequent uptake by tumor cells, whereas plain liposomes enter cells with difficulty. Upon mild heating, the decomposition of ABC that is encapsulated in the liposomes enables the immediate activation of generation of CO2 bubbles, creating permeable defects in their lipid bilayers, and ultimately facilitating the swift intracellular release of DOX. In vivo studies in nude mice that bear tumors demonstrate that the active targeting of AS1411 liposomes can substantially increase the accumulation of DOX in the tumor tissues relative to free DOX or passively targeted plain liposomes, inhibiting tumor growth and reducing systemic side effects, including cardiotoxicity. The above findings indicate that liposomes that are functionalized with AS1411 represent an attractive therapeutic alternative for overcoming the MDR effect, and support a potentially effective strategy for cancer therapy. (C) 2015 Elsevier B.V. All rights reserved.
机译:化疗方面的最新研究已优先克服了癌细胞的多药耐药性(MDR)。在这项工作中,制备包含阿霉素(DOX)和碳酸氢铵(ABC,气泡发生剂)的脂质体,并用抗核苷适体(AS1411脂质体)进行功能化,以靶向抗DOX的乳腺癌细胞(MCF-7 / ADR) ,过表达核仁素受体。未使用AS1411功能化的游离DOX和脂质体(纯脂质体)用作对照。分子动力学模拟的结果表明,AS1411功能化可以促进脂质体与核仁素受体的亲和力和特异性结合,从而增强其随后被肿瘤细胞吸收的能力,而普通脂质体则难以进入细胞。在温和加热下,包裹在脂质体中的ABC分解能够立即激活CO2气泡的产生,在其脂质双层中形成可渗透的缺陷,并最终促进DOX的快速细胞内释放。裸鼠体内有肿瘤的体内研究表明,相对于游离DOX或被动靶向的普通脂质体,AS1411脂质体的主动靶向可显着增加DOX在肿瘤组织中的积累,从而抑制肿瘤生长并降低全身性副作用,包括心脏毒性。上述发现表明,用AS1411功能化的脂质体代表了一种克服MDR效应的有吸引力的治疗选择,并支持潜在的有效癌症治疗策略。 (C)2015 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号